Related Experiment Videos
Bilateral transient hearing loss associated with vincristine therapy: case report
1Inonu University, School of Medicine, Department of Haematology, Turgut Ozal Medical Center, Malatya, Turkey. masevinc@usa.net
Journal of Chemotherapy (Florence, Italy)
|January 12, 2001
Abstract:
Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.